Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.25 USD
−31.39 M USD
0.00 USD
32.62 M
About Quince Therapeutics, Inc.
Sector
Industry
CEO
Dirk Thye
Website
Headquarters
South San Francisco
Founded
2012
FIGI
BBG00BTK1DT8
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of QNCX is 1.96 USD — it has decreased by −5.77% in the past 24 hours. Watch Quince Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Quince Therapeutics, Inc. stocks are traded under the ticker QNCX.
QNCX stock has fallen by −1.01% compared to the previous week, the month change is a 130.59% rise, over the last year Quince Therapeutics, Inc. has showed a 113.04% increase.
We've gathered analysts' opinions on Quince Therapeutics, Inc. future price: according to them, QNCX price has a max estimate of 12.00 USD and a min estimate of 6.00 USD. Watch QNCX chart and read a more detailed Quince Therapeutics, Inc. stock forecast: see what analysts think of Quince Therapeutics, Inc. and suggest that you do with its stocks.
QNCX reached its all-time high on Aug 10, 2021 with the price of 121.98 USD, and its all-time low was 0.51 USD and was reached on Aug 15, 2024. View more price dynamics on QNCX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
QNCX stock is 45.83% volatile and has beta coefficient of −0.39. Track Quince Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Quince Therapeutics, Inc. there?
Today Quince Therapeutics, Inc. has the market capitalization of 86.24 M, it has increased by 16.85% over the last week.
Yes, you can track Quince Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Quince Therapeutics, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
QNCX earnings for the last quarter are −0.13 USD per share, whereas the estimation was −0.17 USD resulting in a 25.00% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about Quince Therapeutics, Inc. earnings.
Quince Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
QNCX net income for the last quarter is −5.49 M USD, while the quarter before that showed −27.73 M USD of net income which accounts for 80.19% change. Track more Quince Therapeutics, Inc. financial stats to get the full picture.
No, QNCX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 32.00 employees. See our rating of the largest employees — is Quince Therapeutics, Inc. on this list?
Like other stocks, QNCX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Quince Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Quince Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Quince Therapeutics, Inc. stock shows the neutral signal. See more of Quince Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.